The gain-of-function mucin 5B (MUC5B) promoter variant, rs35705950, confers the largest risk, genetic or otherwise, for the development of idiopathic pulmonary fibrosis; however, the mechanisms underlying the regulation of MUC5B expression have yet to be elucidated. Here, we identify a critical regulatory domain that contains the MUC5B promoter variant and has a highly conserved forkhead box protein A2 (FOXA2) binding motif. This region is differentially methylated in association with idiopathic pulmonary fibrosis, MUC5B expression, and rs35705950. In addition, we show that this locus binds FOXA2 dynamically, and that binding of FOXA2 is necessary for enhanced expression of MUC5B. In aggregate, our findings identify novel targets to regulate the expression of MUC5B.
Idiopathic pulmonary fibrosis (IPF) is a rapidly progressive and often fatal fibrosing interstitial lung disease. Currently, there is no cure for IPF, and treatment options are only modestly effective. Proteomics (1), epigenomics (2) (3) (4) , and genetics (5, 6) have begun to define the etiology and heterogeneity of this complex disease, and may provide insight into more targeted therapeutics.
Recent genome-wide association studies identified a paradoxical link between a gene encoding a mucin produced in the conducting airways and IPF, the etiology of which is typically thought to be restricted to peripheral alveolar lung origins. The gainof-function promoter variant, rs35705950, is 3 kb upstream of the mucin 5B (MUC5B) transcriptional start site, and is the strongest risk factor (genetic or otherwise) for the development of either sporadic or familial IPF (5) . The association between rs35705950 and IPF has since been replicated in 10 independent cohorts (6) (7) (8) (9) (10) (11) (12) , including a Mexican cohort (13) and two Asian cohorts (14, 15) . However, the penetrance of the MUC5B promoter variant is low, with up to 20% of nonHispanic White subjects having at least one copy of the variant and IPF occurring infrequently. This suggests that factors, in addition to the MUC5B promoter variant, are involved in the development of IPF.
Previous work by our laboratory has determined that the MUC5B promoter variant is associated with a significant increase in MUC5B expression in nonfibrotic lung (5) . Furthermore, the rs35705950 minor allele is sufficient to enhance promoter activity in vitro (16) . Despite the significance of these observations, molecular mechanisms remain unclear. The MUC5B promoter variant, rs35705950, is a G-to-T transversion that occurs in an area of the MUC5B 59 flanking region with elements that are suggestive of a regulatory region (see Figure E1 in the online supplement). Public databases and published work identify evidence for enhancer activity, transcription factor binding, and epigenetic regulation. For example, the area surrounding the MUC5B promoter variant has additional characteristics of an enhancer, including H3K27 acetylation histone marks, a DNase I hypersensitivity site marking open chromatin, and occupancy of a histone modifier (P300) (17) (18) (19) (20) . In addition, motif mapping software suggests that the MUC5B promoter variant, rs35705950, also disrupts an E2F binding site and creates both HOX9 (homeobox A9 [HOXA9]-Meis homeobox 1 [Meis1] heterodimer) and paired box 2 (PAX2) sites, and 19 transcription factors have Ecyclopedia of DNA Elements (ENCODE)-reported chromatin immunoprecipitation sequencing (ChIP-seq) peaks across rs35705950 ( Figure  E1 ). Furthermore, in a gastric cancer cell line, global DNA demethylation through 5-aza-29-deoxycytidine treatment enhances expression of MUC5B (21), suggesting a potential role for DNA methylation in MUC5B regulation. Indeed rs35705950 is in a CpG island (22) , and rs35705950 itself disrupts a CpG motif.
In the present study, our goal is to further elucidate the mechanisms involved in regulation of MUC5B expression in IPF. Based on this evidence of cis-acting genetic and epigenetic regulator elements in the MUC5B promoter, which are strongly associated with rs3570590, we chose to focus on DNA methylation and transcription factor binding in the MUC5B regulatory region. This focus is directly related to critical disease associations in humans. There are established risk factors for IPF that are known to alter the methylome, such as cigarette smoking (23) (24) (25) , asbestos exposure (25, 26) , male sex (27) , and aging (25, 27) . Notably, cigarette smoke is associated with dynamic changes in mucin expression, including induction of MUC5B (28). Moreover, DNA methylation patterns in lung tissue are known to be modified in IPF (4) . Given these observations, we hypothesize that DNA methylation and transcription factor binding contribute to MUC5B regulation, and could consequently contribute to the association between the single nucleotide polymorphism (SNP) and disease risk.
Materials and Methods

Samples
Genotyping, expression, and methylation.
Human lung tissue-derived RNA and DNA were obtained from the NHLBI-Lung Tissue Research Consortium and National Jewish Health-Interstitial Lung Disease Program, including IPF (n = 203) and nonfibrotic control (n = 139) samples. Control tissue was obtained from transplant specimens that failed regional lung selection (National Jewish Health) or biopsies of normal tissue surrounding peripheral lung lesions (Lung Tissue Research Consortium). The diagnosis of IPF was determined by a pathology core consisting of two pulmonary pathologists, a radiology core consisting of three pulmonary radiologists, and a clinical core consisting of five pulmonary physicians. All diagnoses were made in accordance with established criteria (29, 30) . Sample pool for methylation analysis is summarized in Table E1 .
Primary cell culture. Normal human tracheobronchial epithelial cells were obtained from the tracheas of deidentified organ donors whose lungs did not meet the criteria for transplantation (31, 32) . The Institutional Review Board at National Jewish Health approved the collection and the use of these cells.
Genotyping and Expression
Whole lung (DNeasy; Qiagen, Valencia, CA) and peripheral blood DNA (PAXgene blood kits; Qiagen) were used to genotype each individual for rs35705950 using a prevalidated assay (5) . Total RNA isolated from lung tissue from the cases and control subjects was reverse transcribed using SuperScript III reverse transcription kits (Invitrogen, Grand Island, NY) according to the manufacturer's protocol. MUC5B expression levels were determined using a prevalidated MUC5B (Hs00861588_m1) Taqman gene expression assay (Applied Biosystems, Foster City, CA) and normalized to the prevalidated GAPDH (Hs99999905_g1) assay (5) . Relative gene expression data were determined and analyzed using the ΔΔ cycle threshold method (33).
DNA Methylation
CpG-level resolution of DNA methylation was determined using a custom EpiTyper panel by Agena (San Diego, CA; formally Sequenome). Detailed methods are available in supplemental MATERIALS AND METHODS.
ChIP
ChIP was conducted in two cancer cell lines (A549 and LC-2/ad) and two primary human tracheal cells grown at air-liquid interface (ALI). Details for ChIP and quantitative PCR (qPCR) are available in the supplemental MATERIALS AND METHODS.
Reporter Assay
The MUC5B promoter reporter construct (16) was mutated to disrupt the conserved forkhead box protein A2 (FOXA2) binding motif using the Agilent Quikchange II SiteDirected Mutagenesis kit (Santa Clara, CA). Cancer cells (A549 and H358) were transfected with the reporter plasmid, SV40-renilla, and mCherry at a ratio of 10:1:1 using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA). After a 24-hour incubation, luciferase activity was assayed using the Dual Luciferase Reporter assay (Promega, Chicago, IL), and luciferin levels were normalized to renillin levels. Each assay was replicated with similar results.
Short Interfering RNA Knockdown
Dharmafect smartpools were used to knock down the tested transcription factors. Suggested transfection reagent, concentrations, and volumes were used for A549s (96-well format, 0.2 ml Dharmafect 1, and 0.5 ml of 5 mM short interfering RNA (siRNA) per well).
Results rs35705950 and IPF Contribute to the Expression of MUC5B in the Lung
To explore the relationships between rs35705950, IPF, and MUC5B expression, we performed genotyping and expression analysis in a study population of 203 IPF and 139 control samples. Congruent with prior publications (5-12, 14, 15, 34) , the T allele at rs35705950 was present in 51% of patients with IPF and only 23% of control subjects (odds ratio = 3.4; 95% confidence interval [CI] = 2.1-5.5; P = 1.8 3 10 28 ; Figure 1A ). As previously shown, rs35705950 was associated with increased MUC5B gene expression in control subjects (fold change = 34.1; 95% CI = 7.1-162.7; P = 9.8 3 10
26
). In addition, we show a novel correlation between rs35705950 and MUC5B gene expression in subjects with IPF (fold change = 5.7; 95% CI = 2.3-12.6; P = 6.5 3 10
25
; Figure 1B ). MUC5B transcripts were also elevated in subjects with IPF compared with control subjects even after controlling for the variant (fold change = 13.0; 95% CI = 6.1-27.9 fold; P = 1.94 3 10
210
). Taken together, these findings provide further support for the role of the MUC5B promoter variant, rs35705950, and MUC5B expression in lung tissue, and also indicate that factors other than rs35705950 are involved in the transcriptional regulation of MUC5B in patients with IPF.
Methylation of CpG Motifs Adjacent to the MUC5B Promoter Variant Alter the Expression of MUC5B in the IPF Lung
Methylation of the region 4 kb upstream of the MUC5B transcription start site (TSS) was assayed using a mass spectrometry-based method, which allowed for resolution of methylation at individual CpG motifs. Although MUC5B promoter methylation has been previously assayed, the depth and range of detection were limited (21) and methylation of the region 4 kb upstream of the MUC5B TSS has not been previously evaluated in lung tissue from subjects with IPF. In this analysis, we focused on the association between DNA methylation and rs35705950, because the risk allele disrupts a methylation site. We also focused on the association between DNA methylation and MUC5B expression and disease, given that MUC5B expression is dysregulated in IPF. 
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IPF was found to be associated with two differentially methylated regions (DMRs) in the region 4 kb upstream of the MUC5B TSS (Figure 2A ). The 59-most disease-associated DMR consists of 25 CpG motifs that are hypermethylated in the IPF lung, and includes the MUC5B promoter variant, rs35705950 (Chr11: 1241086-1241658; P = 8.8 3 10 259 ). The smaller diseaseassociated DMR consists of four CpG motifs that are hypomethylated in IPF compared with control subjects (Chr11:1244003-1244077; P = 2.5 3 10 27 ) and is immediately upstream of the MUC5B TSS. Both disease-associated DMRs are within areas of open chromatin, and have P300 and H3K27 acetylation ChIP-seq marks ( Figure E1 ), which suggests potential enhancer activity.
Irrespective of disease state, MUC5B expression was found to be associated with a DMR that contains 11 CpG motifs that are hypermethylated (Chr11: 1241139-1241412; P = 4.19 3 10 26 ) in association with increased expression of MUC5B, and contains the MUC5B promoter variant, rs35705950 ( Figure 2B ). Thus, this noncanonical association between expression and methylation is likely explained either by inhibition of repressor binding or binding of a transcription factor with higher affinity to methylated DNA (35, 36) .
Given that the minor allele at rs35705950 disrupts a CpG motif, we investigated the association between the variant and DNA methylation. The MUC5B promoter variant, rs35750590, is associated with a single DMR containing 34 CpG motifs and includes the promoter variant (Chr11: 1240989-1241950; P = 1.08 3 10 239 ; Figure 2C ). When this association is analyzed in nonfibrotic control subjects alone, four DMRs are associated with the polymorphism (Chr11:1240712-1241950, P = 2.13 3 10
2213
; Chr11:1242061-1242473, P = 2.69 3 10
214
; Chr11:1242702-1243421, P = 3.67 3 10
277
; Chr11:1243606-1243691, P = 6.14 3 10 24 ). In subjects with IPF, the associated region is more specific and identifies a single DMR (Chr11:1241559-1241849, P = 2.82 3 10 214 ; Figure E2 ). This finding suggests that the MUC5B promoter variant itself may differentially affect methylation patterns in the MUC5B promoter in subjects with IPF.
When the DMRs are aligned, an overlapping DMR is evident that includes 11
CpG motifs that are associated with IPF, MUC5B expression, and the MUC5B promoter variant. This region is hypermethylated in association with IPF, increased expression of MUC5B in lung tissue, and the rs35705950 risk allele (T). These findings define a regulatory region and support a role for DNA hypermethylation in the regulation of MUC5B expression in the lung and as a risk factor for the development of IPF.
Identification of a Critical Regulatory Domain for MUC5B
Having identified a region of differential methylation associated with IPF, MUC5B expression, and the MUC5B promoter variant, we next applied conservation analysis as a tool to identify potential regulatory sites within this region. In the 1,000 Genomes Project, only three variants were identified within the overlapping DMR, and these variants were found in less Wild Type The FOXA2 binding motif in the MUC5B promoter construct was disrupted using site-directed mutagenesis. A "CT" insert, "AAA" → "C" in/del and a "C" → "T" point mutation were made. (B) The MUC5B wild-type (WT) promoter construct clones (blue; pGL4.10 with MUC5B promoter insert) show that the 4.2-kb region directly upstream of the MUC5B transcriptional start site has increased promoter activity relative to the empty vector (gray; pGL4.10 with no insertions). After site-directed mutagenesis of the conserved FOXA2 motif in the WT reporter, the FOXA2-mutant reporter clones (yellow) show a significant decrease in promoter activity (H358 data shown; P = 1.7 3 10
28
). Twotailed t tests were used for all analyses. Each bar represents an individual clone, with the error bars indicating SEM for technical replicates. EV, empty vector; In/del, dual insertion and deletion. than 1% of the population (Chr11:1241281, 0.137%; Chr11:1241329, 0.137%; Chr11:1241361, 0.458%). Cross-species analysis indicated that the wild-type G allele at rs35705950 is the major allele in primates, including gorilla and gibbon ( Figure E3 ). Collectively, these data suggest that this region of the MUC5B promoter is highly conserved in mammals, and that the bases encoded at the site where the rs35705950 variant occurs in humans represent the 59 border of a region of an unusually strong area of conservation, suggesting that the region contains a conserved element that serves critical gene regulatory functions.
To this end, 32 bp downstream of rs35705950 is a highly conserved region (Chr11:1241262-1241269) containing a FOXA2 binding site (Chr11:1241254-1241270) that is also conserved across mammals ranging from primates to rodents, and includes both terrestrial and aquatic groups ( Figure E3 ). In addition, there are no reported mutations in the FOXA2 binding site (Chr11:1241254-1241270) in the 1,000 Genomes Project or our sample population, further suggesting the evolutionary importance of this region. Based on this conservation across and within species, we postulated that FOXA2 binding may play a role in MUC5B gene regulation.
To determine whether the FOXA2 binding site contributes to transcriptional regulation of MUC5B, we disrupted the conserved FOXA2 motif within a MUC5B promoter reporter that we have described previously (16) (Figure E4 ). Congruent with our prior findings, the parent construct with an intact FOXA2 motif generates significant luciferase activity (16) . However, when the conserved FOXA2 site is disrupted, luciferase activity is markedly decreased (H358 cells, P = 1.7 3 10 28 ; A549 cells, P = 5.9 3 10 29 ; Figure 3B ), suggesting a critical role for the FOXA2 site in regulating MUC5B expression and further defining the critical regulatory domain of MUC5B. These data were further replicated in an additional cell line ( Figure E5 ).
FOXA2 Binds Dynamically to the Critical Regulatory Domain of MUC5B
FOXA2 binding at the predicted motif ( Figure 4A ) was assayed using ChIP-qPCR in the pulmonary adenocarcinoma cell line, LC-2/ad, which expresses high levels of MUC5B (Table E3 ). In LC-2/ad cells, FOXA2 binds in the enhancer region with a 201-fold enrichment relative to negative control regions (P = 1.6 3 10 29 ; Figure 4B ). Enrichment of RNA polymerase II binding was assayed at the TSS to verify the transcriptional activity of MUC5B and at the enhancer as a predictive measure of enhancer activity (37) . RNA polymerase II ) over the negative controls (gray). (C) RNA polymerase II (Pol2) occupancy is enriched for at the TSS (15-fold, P = 0.015), indicating that MUC5B is being actively transcribed. In addition, Pol2 is enriched for at the enhancer, increasing the likelihood that this is an active enhancer motif (14-fold, P = 0.0009). Two-tailed t tests were used for all analyses with results shown as mean (6SEM).
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showed a 15-fold enrichment (P = 0.02) at the TSS and a 14-fold enrichment of occupancy (P = 0.0009) at the enhancer ( Figure 4C ). In aggregate, these findings indicate that MUC5B is actively transcribed in LC-2/ad cells, and also suggest that the MUC5B promoter variant, rs35705950, is located within an active enhancer. Similar results were observed in an additional lung cancer cell line, A549 (Figure E6 ), which expresses lower levels of MUC5B transcript.
Primary human tracheal cells do not produce MUC5B in submerged conditions, but, when cultured at ALI, they differentiate into mucosal and ciliated cells that produce high concentrations of MUC5B (38) . This provides a dynamic model for studying transcriptional control of MUC5B expression. Primary human tracheal cells were grown to confluence and either harvested in a submerged state or moved to ALI and then harvested for ChIP-qPCR. ALI culture is associated with increased transcription complex assembly in comparison to submerged cells ( Figure E7 ). We also measured occupancy of FOXA2 at the 4-kB enhancer in both the submerged and ALI culture conditions, and found that ALI cultures show robust occupancy of FOXA2 at the enhancer site ( Figure 5A ; 62-fold, P = 5.1 3 10
212
). Interestingly, the submerged cultures also have binding of FOXA2 at the enhancer site ( Figure 5B ; 12-fold, P = 1.3 3 10
29
); however, the ALI cultures have a 5.1-fold higher occupancy (P = 1.9 3 10 28 ) compared with the submerged cultures ( Figure 5A ), indicating that binding of FOXA2 is dynamic in association with MUC5B expression. Furthermore, binding of FOXA2 in the submerged cultures may suggest that other components of the transcriptional complex are necessary for the initiation of transcription, thus making FOXA2 a necessary, but not sufficient, initiator of the transcriptional complex. , and zinc finger and BTB domain containing 7A (ZBTB7A) (17.7-fold decrease; 95% CI = 2.9-23.4; P = 3.3 3 10 27 ) also decreased MUC5B expression. Interestingly, the T allele at rs35705950 creates a de novo putative HOXA9-MEIS1 binding site, and STAT3 has been shown to regulate FOXA2 (39) . The FOXA2 siRNA KD was replicated in three additional cell lines, and, in each case, a significant decrease in MUC5B expression was observed (H358, P = 0.039, 1.3-fold; LC-2/ad, P = 0.0084, 1.2-fold; H2122, P = 0.041, 1.3-fold). ) and ALI cultures (12-fold, P = 1.3 3 10
). The relative occupancy of FOXA2 at the enhancer was increased by 5.1-fold (P = 1.9 3 10
28
) in the MUC5B-expressing ALI cultures compared with the nonexpressing submerged cultures. The red bars represent the predicted enhancer site (see Figure 4A) , the green bars represent positive control primers, and the gray bars represent negative control primers. Two-tailed t tests were used for all analyses with results shown as mean (6 SEM).
Discussion
We have identified a highly conserved MUC5B enhancer element that contains the well known MUC5B genetic variant, rs35705950. Here, we show that this enhancer is composed of an overlapping DMR that is associated with expression, IPF, and the presence of the MUC5B promoter variant. This enhancer region in the MUC5B promoter dynamically binds a pioneering transcription factor, FOXA2, as well as RNA polymerase II, together strongly suggestive of an important regulatory function in controlling MUC5B expression. Identification of FOXA2 as a necessary component of the MUC5B transcriptional complex and isolation of the relevant binding regions provide us with the framework both to modify the expression of MUC5B and identify additional factors that contribute to regulation of MUC5B.
DNA methylation remains of particular interest in IPF, given that many of the known risk factors of IPF-male sex, increased age, cigarette smoke exposureare also known to cause changes to the methylome. Here, we indicate that increased methylation is associated with IPF, the risk allele T at rs35705950, and increased expression of MUC5B. Interestingly, although this positive correlation between expression and methylation was once considered paradoxical, more recent studies have indicated that the canonical negative correlation is mostly observed in promoters, whereas enhancers show increased enrichment for positive correlations. This is commonly explained by either increased methylation inhibiting the binding of repressive complexes or binding of a subset of transcription factors that bind with higher affinity to methylated DNA, such as CCCTC-binding factor (CTCF) (40) .
Although the previously identified MUC5B promoter variant, rs35705950, is 32 bp upstream from the FOXA2 binding motif, it is likely that the variant and the binding site function together within a composite regulatory element. There are two probable hypotheses for the interaction between these two sites. First, the MUC5B promoter variant is associated with regional changes in methylation surrounding the FOXA2 binding motif, and this could directly affect FOXA2 occupancy. In this case, we would hypothesize that increased methylation of the surrounding area leads to increased binding of FOXA2. Alternatively, the MUC5B promoter variant may alter the binding affinity/specificity for other transcription factors that interact with or are recruited by FOXA2 to regulate MUC5B expression. In that regard, our data indicate that knockdown of HOXA9, which is predicted to preferentially bind the promoter variant, leads to decreased expression of MUC5B. Intriguingly, the HOX and FOX family of proteins are already known to interact in gene regulation (41, 42) . Moreover, activation of STAT3 is associated with down-regulation of FOXA2 (39) , and, here, we show that knockdown of STAT3 reduces the expression of MUC5B, suggesting that STAT3 may be involved upstream in MUC5B regulation. In addition, FOXA2 is well known to play a key role in early lung development, lung homeostasis (43), surfactant expression, and goblet cell metaplasia (44) , in association with transcription factors, such as GATA binding protein 6 (GATA6) and transcription termination factor 1 (TTF-1). Whether the regulation of MUC5B during disease pathogenesis recapitulates interaction between these transcription factor families during development remains to be determined.
Although age, sex, smoke exposure, and mucin dysregulation are commonly associated with a number of pulmonary diseases (chronic obstructive pulmonary disease, asthma, cystic fibrosis, etc.), the location of mucus production may have a profound effect on the consequent pathophysiological phenotype (45) . For instance, in contrast to IPF, where the excess mucus production is localized to the bronchiole (16), cystic fibrosis (46, 47) and chronic bronchitis (48) are associated with enhanced mucus secretion in more proximal airways and submucosal glands, and consequently these diseases are airway centric. However, too little Muc5b also appears to be detrimental, as we have reported that Muc5b-deficient mice have chronic mucociliary clearance impairment, persistent lung injury and inflammation, and die from bacterial pneumonia (49) . In aggregate, our findings suggest that too little or too much Muc5b leads to different types of lung injury, and that the regulatory components and posttranscriptional processing of Muc5b are finely tuned in the normal lung to . Effects of short interfering RNA (siRNA) knockdown of transcription factors on MUC5B expression. A total of 24 transcription factors predicted to have binding near rs35705950 were knocked down using siRNA, and the effect on MUC5B expression was measured using qPCR. Fold change in MUC5B expression was calculated using the ΔΔCT method, and significance was calculated using a standard t test with a corrected P value of significance of 0.002. Four transcription factors significantly down-regulated MUC5B expression: FOXA2, HOXA9, STAT3, and ZBTB7A (*P , 0.002). CEBPB, CCAAT/enhancer binding protein b; E2F1, E2F transcription factor 1; ELF-1, E74 like ETS transcription factor 1; EP300, E1A binding protein p300; ESR1, estrogen receptor 1; HDAC2, histone deacetylase 2; HNF4, hepatocyte nuclear factor 4; HOXA9, homeobox A9; JUND, JunD proto-oncogene, AP-1 transcription factor subunit; NFIC, nuclear factor I C; PAX, paired box family of transcription factors; REST, RE1 silencing transcription factor; RXRA, retinoid X receptor a; SP1, Sp1 transcription factor; STAT3, signal transducer and activator of transcription 3; TCF12, transcription factor 12; TEAD4, TEA domain transcription factor 4; ZBTB, transcription repressor. Results are shown as the mean of the replicates (6 SEM).
maintain host defense in response to a dynamic and potentially detrimental environment. In addition, we find that the clinical manifestations may, in part, be affected by the location of the defect in mucociliary function. Defining the MUC5B enhancer and identifying FOXA2 as a critical regulator establishes a rationale for pharmacologic targeting of FOXA2 to reduce the expression of MUC5B in IPF. Our work also provides a framework to define additional factors, likely including HOXA9, STAT3, and ZBTB7A that increase MUC5B expression, which is now clearly implicated in IPF pathogenesis, both in association with and independent of the MUC5B promoter variant. Our findings add to the growing body of evidence linking noncoding variants to regulation of gene expression in lung disease, and highlight the importance of integrating genetic and epigenetic variation to uncover novel pathways that are disrupted in lung disease.
Understanding the biological mechanisms underlying the association between genome-wide association study variants and disease is an important next step in the elucidation of critical pathways, identification of targetable components within those pathways, and, ultimately, creation of treatments and cures for a wide range of complex diseases. n
